Enanta Pharmaceuticals, Inc. (FRA:9EP)
Germany
· Delayed Price · Currency is EUR 11.90
-0.10 (-0.83%)
Last updated: Dec 4, 2025, 7:55 PM CET
Enanta Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | 2016 - 2020 |
| Operating Revenue | 65.32 | 67.64 | 79.2 | 86.16 | 97.07 | Upgrade
|
| Revenue | 65.32 | 67.64 | 79.2 | 86.16 | 97.07 | Upgrade
|
| Revenue Growth (YoY) | -3.42% | -14.61% | -8.07% | -11.24% | -20.74% | Upgrade
|
| Gross Profit | 65.32 | 67.64 | 79.2 | 86.16 | 97.07 | Upgrade
|
| Selling, General & Admin | 43.93 | 57.85 | 52.89 | 45.48 | 32.54 | Upgrade
|
| Research & Development | 106.74 | 131.48 | 163.52 | 164.52 | 174.11 | Upgrade
|
| Operating Expenses | 150.67 | 189.33 | 216.41 | 210 | 206.65 | Upgrade
|
| Operating Income | -85.35 | -121.69 | -137.21 | -123.84 | -109.57 | Upgrade
|
| Interest Expense | -7.68 | -10.94 | -5.15 | - | - | Upgrade
|
| Interest & Investment Income | 9.95 | 13.63 | 8.5 | 2.74 | 2.02 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.04 | 0.07 | - | 0.08 | -0.03 | Upgrade
|
| EBT Excluding Unusual Items | -83.05 | -118.93 | -133.85 | -121.02 | -107.58 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.5 | 1.14 | 2.86 | -1.17 | - | Upgrade
|
| Pretax Income | -83.55 | -117.79 | -131 | -122.19 | -107.58 | Upgrade
|
| Income Tax Expense | -1.66 | -1.74 | 2.82 | -0.43 | -28.58 | Upgrade
|
| Net Income | -81.89 | -116.05 | -133.82 | -121.76 | -79 | Upgrade
|
| Net Income to Common | -81.89 | -116.05 | -133.82 | -121.76 | -79 | Upgrade
|
| Shares Outstanding (Basic) | 21 | 21 | 21 | 21 | 20 | Upgrade
|
| Shares Outstanding (Diluted) | 21 | 21 | 21 | 21 | 20 | Upgrade
|
| Shares Change (YoY) | 0.85% | 0.90% | 1.78% | 2.14% | 1.16% | Upgrade
|
| EPS (Basic) | -3.84 | -5.48 | -6.38 | -5.91 | -3.92 | Upgrade
|
| EPS (Diluted) | -3.84 | -5.48 | -6.38 | -5.91 | -3.92 | Upgrade
|
| Free Cash Flow | -32.17 | -96.71 | -112.21 | -86.91 | -70.75 | Upgrade
|
| Free Cash Flow Per Share | -1.51 | -4.57 | -5.35 | -4.22 | -3.51 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -130.66% | -179.92% | -173.23% | -143.74% | -112.88% | Upgrade
|
| Profit Margin | -125.36% | -171.58% | -168.95% | -141.31% | -81.38% | Upgrade
|
| Free Cash Flow Margin | -49.24% | -142.99% | -141.67% | -100.87% | -72.88% | Upgrade
|
| EBITDA | -80.76 | -119.36 | -134.84 | -120.87 | -106.24 | Upgrade
|
| EBITDA Margin | -123.63% | -176.47% | -170.24% | -140.29% | -109.44% | Upgrade
|
| D&A For EBITDA | 4.59 | 2.34 | 2.37 | 2.97 | 3.33 | Upgrade
|
| EBIT | -85.35 | -121.69 | -137.21 | -123.84 | -109.57 | Upgrade
|
| EBIT Margin | -130.66% | -179.92% | -173.23% | -143.74% | -112.88% | Upgrade
|
| Revenue as Reported | 65.32 | 67.64 | 79.2 | 86.16 | 97.07 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.